Elotuzumab: Phase I data

Data from a Phase I trial in 20 evaluable patients who received >=2 cycles of elotuzumab in combination with Velcade bortezomib showed that 60% of patients achieved at least a minor response and 40% achieved at least a partial response. No dose-limiting toxicities were observed during the first cycle of treatment and the MTD was not reached. Patients received 2.5, 5, 10 or 20 mg/kg elotuzumab on days 1 and 11 plus 1.3 mg/m 2 Velcade on days 1, 4, 8 and 11 of a 21-day cycle. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...